title: Bone marrow purging prior to autologous transplantation.
abstract: Our data suggest that ex vivo bone marrow purging using monoclonal antibodies (MoAbs) and sheep-anti-mouse immunobeads (SAM beads) prior to autologous bone marrow transplantation (ABMT) allows satisfactory tumor cell reduction without critical stem cell losses. Nevertheless, there is only a reduction but no elimination of tumor cells. The consequences will have to be clinically discussed.
authors.affiliation: Abteilung für Transfusionsmedizin, Universitätsklinik Erlangen, Erlangen-Nürnberg, BRD.
authors.forename: J
authors.initials: J
authors.lastname: Zingsem
authors.forename: K
authors.initials: K
authors.lastname: Stahlhut
authors.forename: S
authors.initials: S
authors.lastname: Serke
authors.forename: T
authors.initials: T
authors.lastname: Zeiler
authors.forename: V
authors.initials: V
authors.lastname: Weisbach
authors.forename: R
authors.initials: R
authors.lastname: Zimmermann
authors.forename: W
authors.initials: W
authors.lastname: Siegert
authors.forename: R
authors.initials: R
authors.lastname: Eckstein
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D016465:Bone Marrow Purging / Q000295:instrumentation*; D016026:Bone Marrow Transplantation / Q000295:instrumentation* / Q000473:pathology; D002051:Burkitt Lymphoma / Q000473:pathology / Q000601:surgery; D006801:Humans; D007938:Leukemia / Q000473:pathology / Q000601:surgery*; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000473:pathology / Q000601:surgery; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology / Q000601:surgery*; D016399:Lymphoma, T-Cell / Q000473:pathology / Q000601:surgery; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology / Q000601:surgery; D014182:Transplantation, Autologous; D014410:Tumor Stem Cell Assay
chemical_list: D000911:Antibodies, Monoclonal